Leonard Schleifer Net Worth

The estimated Net Worth of Leonard S Schleifer is at least $372 Millón dollars as of 6 June 2024. Leonard Schleifer owns over 787 units of Regeneron Pharmaceuticals stock worth over $73,278,807 and over the last 21 years he sold REGN stock worth over $276,786,606. In addition, he makes $21,455,100 as President, Chief Executive Officer y Director at Regeneron Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Leonard Schleifer REGN stock SEC Form 4 insiders trading

Leonard has made over 46 trades of the Regeneron Pharmaceuticals stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 25,213 units of REGN stock worth $25,610,105 on 11 June 2024.

The largest trade he's ever made was exercising 520,313 units of Regeneron Pharmaceuticals stock on 19 November 2021 worth over $115,030,798. On average, Leonard trades about 91,987 units every 126 days since 2003. As of 6 June 2024 he still owns at least 64,198 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Leonard Schleifer stock trades at the bottom of the page.

Leonard Schleifer biography

Dr. Leonard S. Schleifer M.D., Ph.D. serves as President, Chief Executive Officer, Director of the Company. He founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Regeneron’s founding scientist, Dr. Yancopoulos, built and has managed the Company over the past 32 years. Dr. Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. With over 30 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an in-depth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry. Dr. Schleifer’s significant industry and leadership experience, as well as his extensive knowledge of the Company, led the board to conclude that Dr. Schleifer should serve as a director.

What is the salary of Leonard Schleifer?

As the President, Chief Executive Officer y Director of Regeneron Pharmaceuticals, the total compensation of Leonard Schleifer at Regeneron Pharmaceuticals is $21,455,100. There are 1 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.

How old is Leonard Schleifer?

Leonard Schleifer is 67, he's been the President, Chief Executive Officer y Director of Regeneron Pharmaceuticals since 1994. There are 5 older and 19 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.

Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis y Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Complete history of Leonard Schleifer stock trades at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:

• P. Roy Vagelos,
  Chairman of the Board, Director
• Leonard Schleifer,
  President, Chief Executive Officer, Director
• George Yancopoulos,
  President, Chief Scientific Officer, Director
• Marion McCourt,
  Senior Vice President - Commercial
• Andrew Murphy,
  Executive Vice President - Research
• Neil Stahl,
  Executive Vice President - Research and Development
• Robert Landry,
  Chief Financial Officer, Executive Vice President - Finance
• Daniel Van Plew,
  Executive Vice President, General Manager - Industrial Operations and Product Supply
• Dr. George D. Yancopoulos M.D., Ph.D.,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Dr. Leonard S. Schleifer M.D., Ph.D.,
  Founder, Pres, CEO & Director
• Dr. George D. Yancopoulos,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Robert E. Landry Jr.,
  Exec. VP of Fin. & CFO
• Daniel P. Van Plew,
  Exec. VP and GM of Industrial Operations & Product Supply
• Joseph J. LaRosa,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Andrew J. Murphy,
  Exec. VP of Research
• Arthur Ryan,
  Independent Director
• George Sing,
  Independent Director
• Christine Poon,
  Independent Director
• Michael Brown,
  Independent Director
• Huda Zoghbi,
  Independent Director
• Joseph Goldstein,
  Independent Director
• Bonnie Bassler,
  Independent Director
• N. Anthony Coles,
  Independent Director
• Marc Tessier-Lavigne,
  Independent Director
• Christopher Fenimore,
  Vice President, Controller
• Joseph LaRosa,
  Executive Vice President, General Counsel, Secretary
• Justin Holko,
  VP of Investor Relations
• Bob McCowan,
  Sr. VP of IT & Chief Information Officer
• Gerald Underwood,
  Sr. VP of Technical Operations
• Christopher R. Fenimore,
  Sr. VP, Head of Accounting & Controller
• Patrice Gilooly,
  Sr. VP of Quality Assurance & Operations
• Charles A Baker,
  Director
• Michael S Aberman,
  SVP Strategy Investor Relation
• Sanofi,
  
• Robert J Terifay,
  EVP Commercial
• Alfred G Gilman,
  Director
• Robert Alexander Ingram,
  Director
• Eric M Shooter,
  Director
• Murray A Goldberg,
  SVP Administration & Asst Secr
• Stuart Kolinski,
  SVP General Counsel and Secret
• Amerique Du Nord S.N.C. San...,
  
• Peter Dworkin,
  VP Investor Relations & Commun
• Randall Rupp,
  SVP, Manufuring Operations
• Pharma Ag Novartis,
  10% owner
• Hans Peter Guler,
  VP Clinical Programs
• William Roberts,
  VP Reg Dev & Med Safety
• Peter Powchik,
  SVP Clinical Development & Reg
• Douglas S Mc Corkle,
  VP Controller and Asst Treasur
• Craig B. Thompson,
  Director
• Kathryn Guarini,
  Director
• David P Schenkein,
  Director
• Jason Pitofsky,
  VP Controller